Last updated: September 20, 2026
Eli Lilly is one of the strongest-positioned pharmaceutical companies in the global market, driven by rapid growth in tirzepatide products Mounjaro and Zepbound, a diversified oncology and immunology portfolio, and a large late-stage pipeline. Lilly generated approximately $45.0 billion in 2024 revenue, up from about $34.1 billion in 2023. Mounjaro and Zepbound together generated roughly $16.5 billion, making incretin-based therapies the company’s primary commercial growth engine. [1]
The central competitive issue is whether Lilly can convert tirzepatide’s current demand advantage into durable market leadership before Novo Nordisk, oral obesity-drug developers, generic manufacturers, and next-generation incretin competitors narrow the gap.
How strong is Eli Lilly’s market position in pharmaceuticals?
Lilly holds leading positions in diabetes, obesity, oncology, immunology, neuroscience, and migraine prevention. Its commercial position is strongest in metabolic disease, where tirzepatide combines glucose control and weight loss through dual GIP and GLP-1 receptor activity.
| Business area |
Key Lilly products |
Principal competitors |
2024 strategic position |
| Type 2 diabetes |
Mounjaro, Trulicity, Jardiance partnership |
Novo Nordisk, Merck, AstraZeneca |
Strong, with Mounjaro gaining share |
| Obesity |
Zepbound |
Wegovy, Saxenda, Contrave, Qsymia |
Fastest-growing major franchise |
| Oncology |
Verzenio, Jaypirca, Cyramza |
AstraZeneca, Pfizer, AbbVie, Merck, Roche |
Diversified, led by Verzenio |
| Immunology |
Taltz, Ebglyss |
AbbVie, Johnson & Johnson, Sanofi, Regeneron |
Established, with newer launches |
| Neuroscience |
Kisunla, Emgality, Cymbalta |
Biogen, Eisai, Roche, Amgen |
High pipeline value, regulatory risk |
| Rare disease |
Taltz-adjacent pipeline, enzyme and genetic programs |
Sanofi, Vertex, Sarepta, BioMarin |
Selective rather than dominant |
Mounjaro revenue increased sharply in 2024, while Zepbound established Lilly as the principal challenger to Novo Nordisk in obesity. Verzenio provided a second major growth platform, reducing dependence on a single therapeutic category. [1]
Which companies are challenging Eli Lilly?
Novo Nordisk is Lilly’s most direct competitor. Wegovy and Ozempic established the modern GLP-1 obesity and diabetes markets before Mounjaro and Zepbound reached scale. Novo retains advantages in brand recognition, cardiovascular-outcomes data, manufacturing experience, and global obesity-market access.
Lilly’s principal competitive advantages are:
- Tirzepatide’s dual GIP/GLP-1 mechanism.
- Strong weight-loss results in clinical trials.
- A second branded product, Zepbound, for obesity.
- Accelerating manufacturing investment.
- A broad pipeline of oral and injectable incretin candidates.
Other relevant competitors include:
- Amgen, developing MariTide, an injectable obesity therapy with extended dosing potential.
- Pfizer, developing oral and injectable obesity candidates after discontinuing danuglipron development in 2023.
- Roche, which acquired Carmot Therapeutics and its incretin portfolio.
- Boehringer Ingelheim and Zealand Pharma, developing survodutide.
- Structure Therapeutics, developing oral GLP-1 candidate GSBR-1290.
- Viking Therapeutics, developing VK2735.
- Regeneron and other large-capitalized companies pursuing metabolic programs.
What are Eli Lilly’s principal commercial strengths?
Tirzepatide product architecture
Mounjaro and Zepbound use the same active ingredient, tirzepatide, but address different FDA-approved indications. This allows Lilly to build one manufacturing and clinical platform across diabetes and obesity.
Mounjaro received FDA approval for type 2 diabetes in May 2022. Zepbound received FDA approval for chronic weight management in November 2023. Lilly also obtained FDA approval in December 2024 for Zepbound to treat moderate-to-severe obstructive sleep apnea in adults with obesity, creating a new indication beyond weight loss. [2]
The platform has several commercial benefits:
- One active ingredient supports multiple high-value markets.
- Clinical data can be reused across related indications.
- Manufacturing scale can support both diabetes and obesity demand.
- Prescriber familiarity increases switching and cross-indication adoption.
- Additional indications can extend product growth before patent expiry.
Manufacturing scale
Supply constraints have been a material limitation for both Lilly and Novo Nordisk. Lilly has committed billions of dollars to increasing peptide manufacturing capacity in the United States and Europe. Capital expenditures and acquisitions have focused on active pharmaceutical ingredient production, injectable-device capacity, and finished-dose manufacturing.
The manufacturing barrier is important because a competitor may have a clinically effective molecule but still fail to achieve commercial scale. Lilly’s capacity investments create a barrier against smaller biotechnology companies that lack peptide manufacturing infrastructure.
Oncology diversification
Verzenio, abemaciclib, is Lilly’s most important oncology product. It is approved for HR-positive, HER2-negative early and metastatic breast cancer. The product benefits from adjuvant use, metastatic use, and a large addressable patient population.
Lilly also markets Jaypirca, pirtobrutinib, for selected B-cell malignancies. Jaypirca gives Lilly exposure to a next-generation BTK inhibitor segment that includes AbbVie and Johnson & Johnson’s Imbruvica and AstraZeneca’s Calquence.
Oncology reduces the company’s reliance on diabetes and obesity. It also creates a pipeline opportunity in hematologic malignancies, where treatment sequencing and resistance management can support premium pricing.
Neuroscience pipeline
Lilly’s donanemab, marketed as Kisunla, received FDA approval in July 2024 for early symptomatic Alzheimer’s disease. The approval was based on evidence that donanemab can slow clinical decline, although treatment includes amyloid-related imaging abnormality risks and requires monitoring. [3]
Kisunla competes directly with Eisai and Biogen’s Leqembi. The commercial opportunity is substantial, but uptake depends on diagnostic capacity, infusion infrastructure, Medicare coverage, safety monitoring, and physician willingness to manage risk.
Lilly also markets Emgality for migraine prevention and has late-stage neuroscience programs. Kisunla is strategically valuable but is unlikely to match the immediate revenue scale of Mounjaro and Zepbound.
What patents protect Mounjaro and Zepbound?
Mounjaro and Zepbound are protected by a combination of active-ingredient, formulation, manufacturing, delivery-device, and method-of-use patents. The commercial protection is not limited to a single patent.
| Protection category |
Relevance to tirzepatide products |
| Composition of matter |
Protects the tirzepatide molecule and related peptide structures |
| Formulation |
Covers pharmaceutical compositions, concentrations, stabilizers, and injectable presentations |
| Manufacturing |
Covers production, purification, and processing of tirzepatide |
| Delivery system |
May protect autoinjectors, pens, containers, and administration systems |
| Method of use |
Covers treatment of diabetes, obesity, cardiovascular risk, sleep apnea, and related conditions |
| Regulatory exclusivity |
Includes FDA exclusivity linked to new indications and approvals |
The foundational tirzepatide patent estate is expected to provide protection well into the 2030s, subject to patent-term adjustment, patent-term extension, terminal disclaimers, continuation practice, and the scope of issued claims. FDA Orange Book listings should be evaluated product by product because Mounjaro and Zepbound may have overlapping but not identical listed patents. [4]
When does Mounjaro lose exclusivity?
Mounjaro’s earliest meaningful U.S. generic-entry risk is expected in the mid-2030s based on the core tirzepatide composition-of-matter estate. The exact date depends on the patent claims relied upon by an ANDA applicant and any available patent-term adjustments or extensions.
Regulatory exclusivity does not determine the full commercial entry date. A generic applicant may file an ANDA with a Paragraph IV certification before patent expiry and litigate for approval. FDA approval may be stayed for up to 30 months if the patent holder timely files an infringement action.
When does Zepbound lose exclusivity?
Zepbound is expected to retain significant patent protection into the 2030s. Its obesity and sleep-apnea indications may have separate method-of-use patents and regulatory exclusivity periods. A generic tirzepatide product approved for diabetes could create an indication-specific substitution issue without necessarily authorizing all obesity uses.
This distinction is important. A generic product may enter for one approved indication while remaining restricted from patented uses through a skinny-label strategy. The commercial effect would depend on prescribing behavior, payer policies, state substitution laws, and the strength of method-of-use enforcement.
What is the Orange Book status of Eli Lilly’s leading products?
Lilly’s small-molecule and peptide products are generally evaluated through FDA’s Orange Book, while biologic products are listed in the Purple Book and follow the Biologics Price Competition and Innovation Act pathway.
| Product |
Active ingredient |
FDA category |
Generic or biosimilar risk |
| Mounjaro |
Tirzepatide |
New drug application |
Low near-term risk; significant 2030s patent exposure |
| Zepbound |
Tirzepatide |
New drug application |
Low near-term risk; overlapping tirzepatide estate |
| Trulicity |
Dulaglutide |
New drug application |
Later-cycle risk as patent protection declines |
| Verzenio |
Abemaciclib |
New drug application |
Paragraph IV risk increases near patent expiry |
| Jardiance |
Empagliflozin |
New drug application |
Earlier generic pressure than tirzepatide |
| Taltz |
Ixekizumab |
Biologic license application |
Biosimilar risk after regulatory and patent barriers |
| Emgality |
Galcanezumab |
Biologic license application |
Biosimilar and patent risk in the longer term |
| Kisunla |
Donanemab |
Biologic license application |
No immediate biosimilar threat; complex administration barrier |
The absence of a near-term generic threat does not eliminate pricing risk. Payers can impose utilization controls, preferred-product arrangements, step therapy, and rebate competition before patent expiry.
Are there Paragraph IV challenges to Eli Lilly drugs?
As of the end of 2024, the principal U.S. threat to Mounjaro and Zepbound was competitive development rather than an established generic litigation wave. No approved generic tirzepatide product had entered the U.S. market.
Paragraph IV risk is more developed for mature Lilly products such as older diabetes and oncology products. An ANDA applicant that challenges a listed patent could trigger litigation, a 30-month stay, settlement negotiations, and a potential date-certain launch.
For tirzepatide, the likely sequence is:
- ANDA or other abbreviated application filing.
- Paragraph IV notice to Lilly.
- Patent litigation in federal district court.
- Possible settlement with a licensed entry date.
- Launch after patent expiry or an agreed earlier date.
- Additional litigation involving method-of-use or formulation patents.
What patent litigation affects Eli Lilly?
Lilly has pursued litigation and regulatory actions against companies marketing compounded or allegedly unauthorized versions of tirzepatide. These disputes have involved compounding pharmacies, telehealth businesses, and entities using Lilly trademarks or offering products represented as tirzepatide.
The disputes differ from traditional Paragraph IV litigation. Compounding cases typically involve the Federal Food, Drug, and Cosmetic Act, trademark law, false advertising, state consumer-protection law, and the FDA’s drug-shortage framework. Lilly’s objective is to protect product quality, brand identity, and supply-chain control while limiting unauthorized competition.
The company also faces ordinary product and patent litigation risks in oncology, diabetes, immunology, and biologics. The most financially material future litigation is likely to involve:
- Tirzepatide composition and formulation patents.
- Skinny-label use restrictions.
- Device and injector patents.
- Abemaciclib generic challenges.
- Biosimilar entry against antibody products.
- Pricing and reimbursement disputes.
What licensing deals and acquisitions support Lilly’s strategy?
Lilly combines internal discovery with targeted acquisitions and partnerships.
| Transaction or relationship |
Strategic purpose |
| Boehringer Ingelheim collaboration |
Joint commercialization of Jardiance and other metabolic products |
| Versanis acquisition |
Added bimagrumab and obesity-related development capabilities |
| DICE Therapeutics acquisition |
Added oral and small-molecule immunology programs |
| Morphic acquisition |
Added oral integrin inhibitor MORF-057 and inflammatory-disease capabilities |
| Earlier oncology and neuroscience partnerships |
Expanded access to external innovation and commercial products |
The Morphic acquisition, announced in 2024 at an equity value of approximately $3.2 billion, strengthened Lilly’s position in inflammatory bowel disease through MORF-057. The transaction also demonstrated Lilly’s willingness to use its balance sheet to acquire differentiated clinical assets rather than depend only on internal research. [5]
How does Eli Lilly compare with Novo Nordisk?
| Factor |
Eli Lilly |
Novo Nordisk |
| Lead metabolic products |
Mounjaro and Zepbound |
Ozempic, Wegovy, Rybelsus |
| Mechanism |
Dual GIP/GLP-1 agonism |
Primarily GLP-1 agonism |
| Obesity launch timing |
Later |
Earlier |
| Weight-loss competition |
Strong clinical and commercial momentum |
Larger installed base |
| Oral pipeline |
Expanding |
Strong oral semaglutide platform |
| Manufacturing |
Rapidly expanding |
Extensive existing peptide capacity |
| Cardiovascular evidence |
Developing across tirzepatide programs |
Deep semaglutide outcomes record |
| Patent horizon |
Core protection into the 2030s |
Core semaglutide protection into the 2030s |
| Key risk |
Supply, reimbursement, concentration |
Competition from tirzepatide and next-generation drugs |
Lilly currently has the stronger product-growth trajectory, while Novo Nordisk has a larger established metabolic franchise and deeper historical obesity-market penetration. The market is likely to become multi-product rather than winner-take-all.
What generic launch risks exist for Eli Lilly?
Lilly’s highest near-term generic risks are concentrated in mature small-molecule products and older diabetes therapies. The highest long-term risk concerns tirzepatide.
Generic-entry scenarios include:
- Early Paragraph IV settlement with a date-certain launch.
- At-risk launch after a favorable court ruling.
- Skinny-label entry limited to unpatented indications.
- Authorized generic or licensing arrangement.
- Multiple generic entrants after core patent expiry.
- Price erosion accelerated by payer substitution.
Biologic products face a different risk profile. Biosimilar entry requires substantial clinical, analytical, manufacturing, and regulatory capability. Even after approval, interchangeability, physician confidence, contracting, and administration complexity can slow uptake.
How strong is Eli Lilly’s overall patent estate?
Lilly has a strong but uneven patent estate.
Strongest areas
- Tirzepatide composition, formulation, manufacturing, and use.
- Verzenio oncology indications and formulations.
- New antibody and peptide products with long remaining patent lives.
- Manufacturing know-how and device integration.
- Continuation applications supporting claim diversification.
Weaker areas
- Mature diabetes products approaching generic competition.
- Products dependent on method-of-use claims rather than composition claims.
- Commercial exposure concentrated in a small number of high-revenue products.
- Clinical indications where competing mechanisms may achieve similar outcomes.
- Products facing payer pressure before patent expiry.
The strongest protection comes from a layered estate anchored by composition-of-matter patents. Formulation, manufacturing, device, and method-of-use claims increase litigation complexity but usually do not provide the same exclusionary power as a valid core molecule patent.
What geographic markets matter most for Eli Lilly?
The United States is Lilly’s most important market for tirzepatide because of higher net prices, rapid obesity-drug adoption, and strong commercial coverage potential. Europe offers large patient populations but generally lower prices and more restrictive reimbursement.
China presents a major growth opportunity but includes local pricing pressure, regulatory requirements, and domestic competition. Japan has a developed diabetes market and a distinct reimbursement environment. Emerging markets offer volume growth but contribute less revenue per patient.
International expansion depends on:
- Local regulatory approvals.
- Manufacturing and cold-chain capacity.
- Reimbursement decisions.
- Pricing reference policies.
- Patent enforceability.
- Counterfeit and unauthorized-product controls.
What revenue exposure does Lilly have to tirzepatide?
Tirzepatide has become Lilly’s largest growth driver. Combined Mounjaro and Zepbound revenue of approximately $16.5 billion in 2024 represented more than one-third of total company revenue. [1]
That concentration creates both leverage and risk.
Upside factors
- Expansion into obesity and sleep apnea.
- Improved insurance coverage.
- Higher production capacity.
- International approvals.
- Cardiovascular and metabolic-disease outcomes.
- Oral incretin development.
- Combination therapy with other weight-loss mechanisms.
Downside factors
- Manufacturing delays.
- Reimbursement restrictions.
- Safety concerns or unexpected regulatory findings.
- Superior competing drugs.
- Pricing pressure from payers.
- Compounded or unauthorized versions.
- Patent challenges and settlement risk.
Lilly’s oncology and neuroscience assets provide diversification, but the company’s near-term valuation and growth expectations remain heavily tied to the durability of tirzepatide demand.
Key Takeaways
- Eli Lilly is a leading global pharmaceutical company with its strongest competitive position in obesity and diabetes.
- Mounjaro and Zepbound are the company’s primary growth products and generated approximately $16.5 billion in 2024 revenue.
- Tirzepatide benefits from dual GIP/GLP-1 activity, broad indication potential, and a layered patent estate expected to extend into the 2030s.
- Novo Nordisk remains Lilly’s most important competitor, with advantages in installed base, supply experience, and cardiovascular-outcomes data.
- Verzenio, Jaypirca, Taltz, Emgality, and Kisunla reduce Lilly’s dependence on metabolic products.
- Near-term competition is more likely to come from branded obesity drugs and unauthorized compounded products than from approved generics.
- The most important long-term legal risks are Paragraph IV challenges, skinny-label entry, method-of-use litigation, and biosimilar competition.
- Lilly’s strategic priorities are manufacturing expansion, new tirzepatide indications, oral metabolic drugs, oncology growth, and selective biotechnology acquisitions.
FAQs
What is Eli Lilly’s most valuable product franchise?
Tirzepatide is Lilly’s most valuable franchise. Mounjaro addresses type 2 diabetes, while Zepbound addresses obesity and related conditions.
Is Eli Lilly larger than Novo Nordisk?
By 2024 revenue and overall pharmaceutical diversification, Lilly was larger than Novo Nordisk. Novo remained highly competitive and had greater historical strength in GLP-1 diabetes and obesity products.
Can compounded tirzepatide compete with Mounjaro and Zepbound?
Compounded tirzepatide can create price and access competition, but it does not have the same FDA-approved labeling, manufacturing controls, clinical-data package, or branded distribution system as Lilly’s products.
Will biosimilars threaten Lilly’s obesity franchise?
Biosimilars are not the principal threat to Mounjaro or Zepbound because tirzepatide is a peptide drug regulated through the new drug application pathway. Generic peptide products and patent challenges are more relevant.
What is Lilly’s biggest strategic risk?
The biggest strategic risk is concentration in tirzepatide combined with manufacturing, reimbursement, and competitive risks. A slower-than-expected obesity market or superior next-generation therapy could materially affect Lilly’s growth outlook.
References
- Eli Lilly and Company. (2025). 2024 annual report. https://investor.lilly.com
- U.S. Food and Drug Administration. (2024). FDA approves new medication for chronic weight management, first since 2021. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). FDA approves treatment for adults with Alzheimer’s disease. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov
- Eli Lilly and Company. (2024). Lilly to acquire Morphic to expand immunology pipeline. https://investor.lilly.com
